Wells Fargo upgrades Merck to Overweight; Truist and H.C. Wainwright initiate coverage on BeOne Medicines, MeiraGTx, MannKind, and Fulcrum with Buy ratings and promising price targets.
FDA approves groundbreaking Keytruda (MRK) and Padcev (PFE) combination as first perioperative treatment for muscle-invasive bladder cancer patients who can't receive chemotherapy.
Merck’s WINREVAIR met its goal in a Phase 2 study for CpcPH, a tough heart/lung disease. It helps blood move through the lungs better.
Merck wins bidding war for Cidara Therapeutics at $9.2B, more than double its market value, securing groundbreaking long-acting flu antibody treatment as Big Pharma races for cutting-edge medicines.
Neuphoria Therapeutics initiates strategic review following failed clinical trial. Lynx1 Fund offers $5.20/share buyout as biotech company explores merger and partnership options.
Pfizer announced strong third-quarter profits, allowing it to raise its 2025 profit forecast. This improvement relies on major cost-cutting efforts, even as the company faces fierce competition and a high-stakes legal fight over the obesity startup Metsera.
